References
- Luchsinger JA. Type 2 diabetes and cognitive impairment: linking mechanisms. J. Alzheimers Dis. 2012;30(2):S185–S198.
- Craft S. The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Arch Neurol. 2009;66(3):300–305.
- Launer LJ, Miller ME, Williamson JD, et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011;10:969–977.
- de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer’s disease. Drugs. 2012;72:49–66.
- Craft S, Newcomer J, Kanne S, et al. Memory improvement following induced hyperinsulinemia in alzheimer’s disease. Neurobiol Aging. 1996;17(1):123–130.
- Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91(3):795–826.
- Despa S, Margulies KB, Chen L, et al. Hyperamylinemia contributes to heart dysfunction in obesity and diabetes, a study in humans and rats. Circ Res. 2012;110(4):598–608.
- Erickson JR, Pereira L, Wang L, et al. Diabetic hyperglycemia activates CaMKII and arrhythmias by O linked glycosylation. Nature. 2013;502(7471):372–376.
- Despa S, Despa S, Sharma S, et al. Cardioprotection by controlling hyperamylinemia in a “humanized” diabetic rat model. J Am Heart Assoc. 2014. DOI:10.1161/JAHA.114.001015.
- Jackson K, Barisone G, Jin L-W, et al. Amylin deposition in the brain: a second amyloid in Alzheimer disease? Ann Neurol. 2013;74(4):517–526.
- Fawver JN, Ghiwot Y, Koola C, et al. Islet amyloid polypeptide (IAPP): a second amyloid in Alzheimer’s disease. Curr Alzheimer Res. 2014;11:928–940.
- Oskarsson ME, Paulsson JF, Schultz SW, et al. In vivo seeding and cross-seeding of localized amyloidosis: a molecular link between type 2 diabetes and Alzheimer disease. Am J Pathol. 2015;185:834–846.
- Lim YA, Rhein V, Baysang G, et al. Abeta and human amylin share a common toxicity pathway via mitochondrial dysfunction. Proteomics. 2010;10(8):1621–1633.
- Jhamandas JH, Mactavish D. Antagonist of the amylin receptor blocks beta-amyloid toxicity in rat cholinergic basal forebrain neurons. J Neurosci. 2004;24(24):5579–5584.
- Srodulski S, Sharma S, Bachstetter AB, et al. Neuroinflammation and neurologic deficits in diabetes linked to brain accumulation of amylin. Mol Neurodegener. 2014;9:30.
- Biessels GJ, Gispen WH. The impact of diabetes on cognition: what can be learned from rodent models? Neurobiol Aging. 2005;26(Suppl 1):36–41.
- Banks WA, Kastin AJ. Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amylin. Peptides. 1998;19(5):883–889.
- Tucker HM, Rydel RE, Wright S, et al. Human amylin induces “apoptotic” pattern of gene expression concomitant with cortical neuronal apoptosis. J Neurochem. 1998;71(2):506–516.
- Edvinsson L, Goadsby PJ, Uddman R. Amylin: localization, effects on cerebral arteries and on local cerebral blood flow in the cat. Sci World J. 2001;1:168–180.
- Zhu H, Wang X, Wallack M, et al. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer’s disease. Mol Psychiatry. 2015;20(2):252–262.